Diacomit FDA Approval History
FDA Approved: Yes (First approved August 20, 2018)
Brand name: Diacomit
Generic name: stiripentol
Dosage form: Capsules and Powder for Oral Suspension
Treatment for: Dravet Syndrome
Diacomit (stiripentol) is an anticonvulsant indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam.
Development Timeline for Diacomit
|Aug 21, 2018||FDA Approves Diacomit (stiripentol) for Seizures Associated with Dravet Syndrome|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.